In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

NICE is also looking at the role of Hympavzi in treating severe haemophilia A, where there are other subcutaneous options ...